首页 / 院系成果 / 成果详情页

SLL) 会议论文

编号：

C3DDBE6AD2ABDC52DC4472F08DEEE12B
作者：

Yi, Shuhua^[1] Zhou, Keshu^[2] Liu, Ning^[3] Sang, Wei^[4] Huang, Rui^[5] Wang, Yi^[6] Zhang, Chenghui^[7] Wu, Fudao^[8] Li, Ying^[9] Sun, Mei^[10] Mi, JianQing^[11] Ding, Kaiyang^[12] Gao, Sujun^[13] Zhang, Qiaohua^[14] Hua, Haiying^[15] Chu, Xiaoxia^[16] Cheng, Jian^[17] Abudureyimu, Aikebaier^[18] Zhou, Lanyun^[19] Chow, Cheryl^[20] Chen, Tianlei^[20] Liang, Zhiyu^[19] Vezan, Remus^[20] Qiu, Lugui^[21,22]
语种：

英文
会议名称：

BLOOD
收录：
高质量科技期刊分级目录：

T1
推荐引用方式
GB/T 7714：

Yi Shuhua,Zhou Keshu,Liu Ning, et al. Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) [J].BLOOD,2025,146:5666-5667.
APA：

Yi Shuhua,Zhou Keshu,Liu Ning,Sang Wei,&Qiu Lugui.(2025).Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) .BLOOD,146:5666-5667.
MLA：

Yi Shuhua, et al. "Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)" .BLOOD 146(2025):5666-5667.
入库时间：

2/2/2026 9:06:44 AM
更新时间：

2/11/2026 9:33:05 PM

浏览次数：8  下载次数：0

分享到：

浏览次数：8

下载次数：0

打印次数：0